Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

Abstract Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signa...

Full description

Bibliographic Details
Main Authors: Zhenzhen Fan, Yahui Tian, Zhipeng Chen, Lu Liu, Qian Zhou, Jingjing He, James Coleman, Changjiang Dong, Nan Li, Junqi Huang, Chenqi Xu, Zhimin Zhang, Song Gao, Penghui Zhou, Ke Ding, Liang Chen
Format: Article
Language:English
Published: Springer Nature 2020-05-01
Series:EMBO Molecular Medicine
Subjects:
immunotherapy
methylene blue
PD‐1
small molecular inhibitor
transgenic mouse model
Online Access:https://doi.org/10.15252/emmm.201911571

Internet

https://doi.org/10.15252/emmm.201911571

Similar Items